Moderna Inc. announced positive interim results from a Phase 1/2 clinical study evaluating its investigational pandemic influenza vaccine, mRNA-1018. The study, involving approximately 300 healthy adults aged 18 and older, assessed the safety and immunogenicity of the vaccine targeting the H5 avian influenza virus subtype. Results indicated a robust immune response, with 97.8% of participants achieving protective antibody levels three weeks after the second dose. The vaccine was generally well-tolerated with no significant safety concerns. Despite positive findings, Moderna was informed that the U.S. Department of Health and Human Services will terminate the award for late-stage development. The company plans to explore alternative paths for advancing the program.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.